Review
Environmental Sciences
Oliwia Zakerska-Banaszak, Liliana Lykowska-Szuber, Michal Walczak, Joanna Zuraszek, Aleksandra Zielinska, Marzena Skrzypczak-Zielinska
Summary: The effectiveness of thiopurine drugs in inflammatory bowel disease (IBD) has been confirmed for more than 50 years. Despite controversies over their cytotoxic properties and adverse effects, thiopurines are still widely used for maintaining remission in Crohn's disease and ulcerative colitis. Further research is needed to explore the modulation of thiopurine action in combination therapy and their interaction with the gut microbiota.
Article
Multidisciplinary Sciences
Debbie S. Deben, Rob H. Creemers, Arjan J. van Adrichem, Roosmarie Drent, Audrey H. H. Merry, Mathie P. G. Leers, Adriaan A. van Bodegraven, Dennis R. Wong
Summary: This study aimed to investigate whether protein levels of Rac1 and pSTAT3 in T lymphocytes can serve as specific pharmacodynamic markers for thiopurine therapy in IBD patients. The results showed that the ratio of Rac1 and pSTAT3 protein levels was lower in the thiopurine treatment groups, indicating potential predictive value for therapeutic effectiveness in IBD patients receiving thiopurine monotherapy.
SCIENTIFIC REPORTS
(2022)
Review
Medical Laboratory Technology
Rishi Bolia, Akhil Goel, Anshu Srivastava
Summary: This meta-analysis suggests a potential association between 6-thioguanine nucleotide (6-TGN) levels and biochemical remission in autoimmune hepatitis (AIH). Further studies are needed to determine the therapeutic cutoff point for 6-TGN.
THERAPEUTIC DRUG MONITORING
(2021)
Article
Medical Laboratory Technology
Sofia A. W. van Moorsel, Debbie S. Deben, Rob H. Creemers, Bjorn Winkens, Paul Bus, Marieke J. Pierik, Melek Simsek, Nanne K. H. de Boer, Adriaan A. van Bodegraven, Dennis R. Wong
Summary: This study aimed to validate and optimize predictive algorithms for thiopurine-associated hepatotoxicity, but found limited accuracy in predicting liver toxicity. Factors contributing to this outcome included changes in prescription behavior over time and lower dosages of MP being prescribed.
THERAPEUTIC DRUG MONITORING
(2022)
Article
Gastroenterology & Hepatology
Andrea Cassinotti, Alberto Corona, Piergiorgio Duca, Manuela Nebuloni, Giovanni Maconi, Paolo Fociani, Sandro Ardizzone
Summary: More than half of UC patients and one-third of CD patients relapse after AZA withdrawal despite previous deep remission. FC positivity is associated with high risk of relapse, allowing early correction of the therapeutic strategy.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Alex Barnes, Soong-Yuan J. Ooi, Kate D. Lynch, Nina Parthasarathy, Maria Bishara, Michael Gounder, Rachel Grafton, Peta Leach, Peter Bampton, Alexandra Sechi, Watson Ng, Susan Connor, Daniel van Langenberg, Reme Mountifield, Jane M. Andrews
Summary: This study aimed to evaluate the long-term outcomes of patients on thiopurines following therapeutic drug monitoring (TDM) for the treatment of inflammatory bowel disease (IBD). The findings showed that TDM resulted in a change in management for the majority of patients and led to an increase in the number of patients in remission. Proactive TDM allowed for the identification and management of inappropriate dosing and was associated with higher levels of clinical remission.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Medical Laboratory Technology
Xuemei Luo, Simin Yan, Lu Jin, Huaijun Zhu, Xiaoqi Zhang, Weihong Ge
Summary: This study found that ITPA genotypes and 6-TGN concentration were associated with the clinical effectiveness of azathioprine, with patients carrying ITPA variant alleles exhibiting higher 6-TGN levels. Additionally, the relationship between NUDT15 and leukopenia and neutropenia was confirmed.
THERAPEUTIC DRUG MONITORING
(2022)
Article
Gastroenterology & Hepatology
Ashkan Rezazadeh Ardabili, Steven Jeuring, Zlatan Mujagic, Liekele Oostenbrug, Marielle Romberg-Camps, Daisy Jonkers, Adriaan van Bodegraven, Marieke Pierik
Summary: In this population-based cohort study, thiopurine monotherapy was found to be an effective, safe, and durable treatment option for patients with inflammatory bowel disease (IBD), including both Crohn's disease (CD) and ulcerative colitis (UC), regardless of the era of initiation.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Immunology
Shailesh Perdalkar, Pooja Basthi Mohan, Balaji Musunuri, Siddheesh Rajpurohit, Shiran Shetty, Krishnamurthy Bhat, Cannanore Ganesh Pai
Summary: This review provides evidence on the risk of COVID-19 infection and its severe prognosis in IBD patients on Thiopurine therapy. The results suggest that Thiopurine therapy is safe during the pandemic and does not increase the risk when used alone or in combination with other IBD drugs. Additionally, in vitro studies indicate that Thiopurine may have a potential therapeutic role against beta coronaviruses.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Gastroenterology & Hepatology
Emma Flanagan, Emily K. Wright, Winita Hardikar, Miles P. Sparrow, William R. Connell, Michael A. Kamm, Peter De Cruz, Steven J. Brown, Alexander Thompson, Anthea Greenway, Ian Westley, Murray Barclay, Alyson L. Ross, Katerina V. Kiburg, Sally J. Bell
Summary: Maternal 6-TGN levels decrease and 6-MMP levels increase in the second trimester of pregnancy. Infants are exposed to low levels of thiopurine metabolites which are cleared by 6 weeks with no anaemia.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Oncology
Keita Kawakado, Kazuhisa Nakashima, Hiroshi Tobita, Mamiko Nagase, Ken Yoshihara, Mika Horie, Megumi Hamaguchi, Tamio Okimoto, Yukari Tsubata, Takeshi Isobe
Summary: An 82-year-old man with malignant pleural mesothelioma was treated with ipilimumab and nivolumab. Despite previous treatment with prednisolone for immune-related adverse event hepatitis, his liver function worsened. After trying different medications, a combination of mercaptopurine and prednisolone improved his liver function and allowed for the gradual reduction of prednisolone dose. This case highlights the potential effectiveness of thiopurine-based immunosuppressants for steroid-refractory hepatitis.
Article
Gastroenterology & Hepatology
Remi Mahmoud, Hans-Paul Schultheiss, Jonas Louwers, Michiel van der Kaaij, Boris van Hellemondt, Nofel Mahmmod, Petra van Boeckel, Bindia Jharap, Herma Fidder, Bas Oldenburg
Summary: The benefit of concomitant immunomodulators in patients with inflammatory bowel disease on anti-TNF maintenance therapy is uncertain. This study found that withdrawing the immunomodulator did not increase the risk of loss of response in the following 1-2 years, but it did lead to a higher detection of anti-drug antibodies.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Health Care Sciences & Services
Heh-Shiang Sheu, Yi-Ming Chen, Yi-Ju Liao, Chia-Yi Wei, Jun-Peng Chen, Hsueh-Ju Lin, Wei-Ting Hung, Wen-Nan Huang, Yi-Hsing Chen
Summary: This study investigated the correlation between TPMT polymorphisms and AZA-related hepatotoxicity in Asian patients. The results showed that the non-normal metabolizer genotype of TPMT was associated with hepatotoxicity. The incidence of hepatotoxicity was higher in the non-normal metabolizer group compared to the normal metabolizer group, and increased over time.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Amol O. Bajaj, Mark M. Kushnir, Erik Kish-Trier, Rachel N. Law, Lauren M. Zuromski, Alejandro R. Molinelli, Gwendolyn A. McMillin, Kamisha L. Johnson-Davis
Summary: We developed an LC-MS/MS method for monitoring the concentrations of 6-TG and 6-MMP and evaluated the stability of thiopurine metabolites. The method showed good agreement with other methods and revealed differences in metabolite concentrations among different TPMT groups and age groups.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Gastroenterology & Hepatology
Sandra Bohn Thomsen, Ryan C. Ungaro, Kristine H. Allin, Rahma Elmahdi, Gry Poulsen, Mikael Andersson, Jean-Frederic Colombel, Tine Jess
Summary: This study assessed the impact of discontinuing or continuing thiopurine therapy on anti-TNF treatment. The results showed that discontinuing thiopurine therapy within 90 days of anti-TNF initiation increased the risk of adverse outcomes, particularly hospitalizations and the use of oral corticosteroids.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Oncology
Yasuyuki Okada, Fuduan Peng, Jose Perea, Luis Corchete, Luis Bujanda, Wei Li, Ajay Goel
Summary: A novel methylation signature risk-scoring model was developed to reliably identify patients with synchronous colorectal cancer (SyCRC), which has the potential to improve the diagnosis and management of colorectal cancer (CRC) patients.
BRITISH JOURNAL OF CANCER
(2023)
Article
Gastroenterology & Hepatology
Laurent Peyrin-Biroulet, Jean-Francois Rahier, Julien Kirchgesner, Vered Abitbol, Sebastian Shaji, Alessandro Armuzzi, Konstantinos Karmiris, Javier P. Gisbert, Peter Bossuyt, Ulf Helwig, Johan Burisch, Henit Yanai, Glen A. Doherty, Fernando Magro, Tamas Molnar, Mark Lowenberg, Jonas Halfvarson, Edyta Zagorowicz, Helene Rousseau, Cedric Baumann, Filip Baert, Laurent Beaugerie
Summary: The I-CARE study aims to evaluate the benefit-risk ratio of current therapies in IBD patients. It collected data from 10,206 patients and observed the treatment risks of anti-tumor necrosis factor and other biologic therapies, particularly the risks of cancer/lymphoma and serious infections. The results showed that different treatment regimens had varying effects on patients, and further research is needed to assess specific risks.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Manuel Barreiro-de Acosta, Agnes Fernandez-Clotet, Francisco Mesonero, Francisco Javier Garcia-Alonso, Maria Jose Casanova, Margarita Fernandez-de la Varga, Fiorella Canete, Luisa de Castro, Ana Gutierrez, Beatriz Sicilia, Victoria Cano, Olga Merino, Ruth de Francisco, Irene Gonzalez-Partida, Gerard Suris, Leyanira Torrealba, Rocio Ferreiro-Iglesias, Beatriz Castro, Lucia Marquez, Ana Sobrino, Ainara Elorza, Xavier Calvet, Pilar Varela, Raquel Vicente, Luis Bujanda, Laura Lario, Noemi Mancenido, Mariana F. Garcia-Sepulcre, Eva Iglesias, Cristina Rodriguez, Marta Piqueras, Juan Angel Ferrer Rosique, Alfredo J. Lucendo, Olga Benitez, Melody Garcia, David Olivares, Carlos Gonzalez-Munoza, Beatriz Lopez-Cauce, Victor Jair Morales Alvarado, Katerina Spicakova, Alicia Brotons, Fernando Bermejo, Pedro Almela, Nahia Ispizua, Pau Gilabert, Carlos Tardillo, Fernando Munoz, Pablo Navarro, Rosa Eva Madrigal Dominguez, Pau Sendra, Esther Hinojosa, Empar Sainz, Maria Dolores Martin-Arranz, Daniel Carpio, Elena Ricart, Berta Caballol, Laura Nunez, Jesus Barrio, Javier P. Gisbert, Marisa Iborra, Margalida Calafat, Vicent Hernandez, Roser Munoz Perez, Jose Luis Cabriada, Eugeni Domenech, Iago Rodriguez-Lago
Summary: This study evaluated the effectiveness of biologic agents in Crohn's disease complicated with internal fistulizing disease. It found that biologic therapy is beneficial for approximately three-quarters of patients, achieving a fistula closure rate of 24%, but around one-third of patients still require surgery. Patient- and lesion-related factors can identify patients who will obtain more benefit from these drugs.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Luigi Gatta, Olga P. Nyssen, Giulia Fiorini, Ilaria Maria Saracino, Matteo Pavoni, Marco Romano, Antonietta Gerarda Gravina, Lucia Granata, Rinaldo Pellicano, Antonio Gasbarrini, Alfredo Di Leo, Giuseppe Losurdo, Francesco Franceschi, Gerardo Nardone, Alba Rocco, Maria Pina Dore, Fabio Farinati, Matteo Ghisa, Massimo Bellini, John Holton, Ignasi Puig, Dino Vaira, Claudio Borghi, Francis Megraud, Colm O'Morain, Javier P. Gisbert
Summary: This study evaluated the effectiveness and safety of empirical first- and second-line treatments for Helicobacter pylori patients. Only quadruple therapies lasting at least 10 days achieved over 90% eradication rates, and high-dose PPI twice daily improved the effectiveness of some treatments.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2023)
Article
Oncology
Ivan Guerra, Luis Bujanda, Miriam Manosa, Isabel Perez-Martinez, Maria Jose Casanova, Luisa de la Pena, Marina de Benito, Montserrat Rivero, Pilar Varela, Lorena Bernal, Ana Carolina Franco, Yolanda Ber, Marta Piqueras, Carlos Tardillo, Angel Ponferrada, Sonsoles Olivares, Alfredo J. J. Lucendo, Pau Gilabert, Monica Sierra Ausin, Maria Bellart, Amaia Herrarte, Margalida Calafat, Ruth de Francisco, Javier P. Gisbert, Jordi Guardiola, Eugeni Domenech, Fernando Bermejo
Summary: An increased risk of lymphoma has been found in patients with inflammatory bowel disease (IBD). This study aimed to analyze the management and evolution of lymphomas in IBD patients. The majority of IBD patients had been treated with thiopurines and/or anti-TNF agents before lymphoma diagnosis, and these treatments did not impact the relapse and mortality of lymphoma.
Article
Biochemistry & Molecular Biology
Rosario Medina-Medina, Eva Iglesias-Flores, Jose M. Benitez, Sandra Marin-Pedrosa, Isabel Salgueiro-Rodriguez, Clara I. Linares, Sandra Gonzalez-Rubio, Pilar Soto-Escribano, Beatriz Gros, Manuel L. Rodriguez-Peralvarez, Jose L. Cabriada, Maria Chaparro, Javier P. Gisbert, Eduardo Chicano-Galvez, Ignacio Ortea, Gustavo Ferrin, Valle Garcia-Sanchez, Patricia Aguilar-Melero
Summary: Therapy with anti-TNF has transformed the treatment of Crohn's disease, but long-term efficacy is limited and adverse events can occur. This study aimed to find reliable markers to predict response to anti-TNF drugs in Crohn's disease patients. By comparing protein expression profiles in plasma samples, we identified 18 differentially expressed proteins, including vinculin, that may serve as biomarkers for short-term remission. Plasma vinculin levels, along with other factors such as baseline CD Activity Index, corticosteroid induction, and bowel resection, can predict non-short-term remission.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Biographical-Item
Gastroenterology & Hepatology
Albert Martin-Cardona, Anna Carrasco, Maria Esteve
GASTROENTEROLOGIA Y HEPATOLOGIA
(2023)
Article
Gastroenterology & Hepatology
Emily K. Wright, Maria Chaparro, Paolo Gionchetti, Amy L. Hamilton, Julien Schulberg, Javier P. Gisbert, Maria Chiara Valerii, Fernando Rizzello, Peter De Cruz, John C. Panetta, Annelie Everts-van der Wind, Michael A. Kamm, Thierry Dervieux
Summary: This study found that adalimumab drug clearance is a critical factor in determining the therapeutic outcome of Crohn's disease patients. Patients with lower drug clearance showed better endoscopic remission, while drug concentration did not significantly differ between patients in remission and those with recurrence. Sustained clinical remission based on C-reactive protein and lower faecal calprotectin levels were generally associated with lower clearance and higher drug concentration.
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Gastroenterology & Hepatology
Javier P. Gisbert, Maria Chaparro
Summary: The de-escalation of biologic therapy in inflammatory bowel disease (IBD) carries risks and uncertainties and should be tailored to individual patients.
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
F. Casellas Jorda, C. Rodriguez, J. P. Gisbert, S. Bernardo, J. Aparicio, I. Tagarro, F. Munoz
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
M. Chaparro, D. Acosta, C. Rodriguez, F. Mesonero, M. Vicuna, M. Barreiro-de Acosta, A. Fernandez-Clotet, A. Hernandez Martinez, M. Arroyo, I. Vera, A. Ruiz-Cerulla, B. Sicilia, M. J. Cabello Tapia, C. Munoz Villafranca, J. Castro-Poceiro, J. Martinez Cadilla, M. Sierra-Ausin, M. Vazquez Moron, E. Montil Miguel, F. Bermejo, V. Royo, M. Calafat, C. Gonzalez-Munoza, E. Leo Carnerero, N. Mancenido Marcos, L. Torrealba, H. Alonso-Galan, M. Benitez, Y. Ber Nieto, M. T. Diz-Lois Palomares, M. J. Garcia, J. F. Munoz, E. M. Armesto Gonzalez, X. Calvet, A. Hernandez-Camba, R. E. Madrigal Dominguez, L. Menchen, J. L. Perez Calle, M. Piqueras, J. P. Gisbert
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
M. Chaparro, M. Garcia Donday, S. Rubio, C. Calvino Suarez, A. Nunez Ortiz, M. Figueira, S. Marin Pedrosa, M. Rivero, A. Fernandez-Clotet, L. Madero, M. T. Diz-Lois Palomares, I. Perez-Martinez, A. Ruiz-Cerulla, M. Arroyo, M. Piqueras, C. Suarez Ferrer, M. Aguas, M. Calvo Moya, I. Guerra, P. Lopez Serrano, J. M. Vazquez Moron, L. Arias Garcia, M. J. Casanova, J. M. Huguet, G. Valldosera Gomis, B. Zuniga de Mora-Figueroa, R. Armesto, P. Martinez Montiel, I. Rodriguez-Lago, P. Sendra Rumbeu, R. Camargo Camero, D. Hervias Cruz, G. Molina Arriero, M. Barreiro-de Acosta, D. Acosta, Y. Brenes, S. Hermida, P. Parra, A. Garre, J. P. Gisbert
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
I. Soleto, A. C. Marin, I. Mora, J. R. Villagrasa, M. Baldan-Martin, C. Ramirez, D. Bernardo, M. Chaparro, J. P. Gisbert
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
I. Soleto, M. Baldan, C. Ramirez, M. Orejudo, S. Garcia, J. Mercado, M. Azkargorta, I. Lloro, L. Ortega Moreno, L. Aldars Garcia, S. Riestra, M. Rivero, A. Gutierrez, I. Rodriguez-Lago, L. Fernandez, D. Ceballos, J. M. Benitez, M. Aguas, I. Baston Rey, F. Bermejo, M. J. Casanova, R. Lorente, Y. Ber, D. Ginard, M. Esteve, F. Elortza, J. P. Gisbert, N. Martin-Cofreces, M. Chaparro
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
I. Soleto, C. Ramirez, C. Gomez, B. Montse, S. Garcia, M. Orejudo, J. Mecado, M. Chaparro, J. P. Gisbert
JOURNAL OF CROHNS & COLITIS
(2023)